Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$103.02 USD
+1.64 (1.62%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $103.04 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AXSM 103.02 +1.64(1.62%)
Will AXSM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AXSM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AXSM
Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
AXSM: What are Zacks experts saying now?
Zacks Private Portfolio Services
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study
Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment
Why Is Axsome (AXSM) Down 1.8% Since Last Earnings Report?
Other News for AXSM
A Look at Axsome Therapeutics's Upcoming Earnings Report
Axsome: Some Recent Setbacks, Some Recent Wins -- Still A Buy
Axsome Therapeutics Breaks Below 200-Day Moving Average - Notable for AXSM
Axsome Therapeutics (AXSM) to Highlight CNS Pipeline at R&D Day | AXSM Stock News
Axsome Therapeutics Inc (AXSM) Hosts Frontiers in Brain Health R&D Day | AXSM stock news